OBJECTIVES: Despite the fact that there are individuals who have chronic HIV infection, few studies have investigated ART interruption in this setting. The aim of this study was to evaluate the ability to spontaneously control viral replication during analytical treatment interruption (ATI) in adults with chronic HIV-1 infection, on ART, with suppressed viraemia for >10 years and with a low reservoir. PATIENTS AND METHODS: This was a prospective, open-label, single-arm, non-randomized, proof-of-concept study (NCT03198325) of subjects with chronic HIV-1 infection, HIV-RNA <50 copies/mL for ≥10 years, without residual viraemia for ≥5 years, CD4+ >500 cells/mm3, HIV-DNA <100 copies/106 PBMCs and without comorbidities or AIDS-defining diseases. Enrolled patients were strictly monitored. The ART regimen in use at ATI was resumed in the case of confirmed viral rebound (CVR, two consecutive HIV-RNA >50 copies/mL). Results are reported as median (IQR). RESULTS: Nine patients underwent ATI. All participants experienced CVR [4.84 (IQR: 3.47-6.47) HIV-RNA log10 copies/mL] after ATI at a median time of 21 days (range 14-56) and restarted ART. After ART resumption, all the subjects achieved HIV-RNA <50 copies/mL in a median of 88 days (range 15-197). No serious adverse event occurred; one subject experienced acute retroviral syndrome. No significant correlation between baseline factors and time to viral rebound was observed, while the magnitude of viral rebound was significantly associated with pre-ART HIV-1 RNA (Spearman r = 0.786, P = 0.036), nadir CD4+ (Spearman r = -0.800, P = 0.010), baseline CD4+ (Spearman r = -0.667, P = 0.049) and years with undetectable viral load (Spearman r = -0.717, P = 0.030). CONCLUSIONS: Despite a long period of HIV viral load suppression and a low viral reservoir, early and consistent viral rebound was observed during ATI in all subjects.
OBJECTIVES: Despite the fact that there are individuals who have chronic HIV infection, few studies have investigated ART interruption in this setting. The aim of this study was to evaluate the ability to spontaneously control viral replication during analytical treatment interruption (ATI) in adults with chronic HIV-1 infection, on ART, with suppressed viraemia for >10 years and with a low reservoir. PATIENTS AND METHODS: This was a prospective, open-label, single-arm, non-randomized, proof-of-concept study (NCT03198325) of subjects with chronic HIV-1 infection, HIV-RNA <50 copies/mL for ≥10 years, without residual viraemia for ≥5 years, CD4+ >500 cells/mm3, HIV-DNA <100 copies/106 PBMCs and without comorbidities or AIDS-defining diseases. Enrolled patients were strictly monitored. The ART regimen in use at ATI was resumed in the case of confirmed viral rebound (CVR, two consecutive HIV-RNA >50 copies/mL). Results are reported as median (IQR). RESULTS: Nine patients underwent ATI. All participants experienced CVR [4.84 (IQR: 3.47-6.47) HIV-RNA log10 copies/mL] after ATI at a median time of 21 days (range 14-56) and restarted ART. After ART resumption, all the subjects achieved HIV-RNA <50 copies/mL in a median of 88 days (range 15-197). No serious adverse event occurred; one subject experienced acute retroviral syndrome. No significant correlation between baseline factors and time to viral rebound was observed, while the magnitude of viral rebound was significantly associated with pre-ART HIV-1 RNA (Spearman r = 0.786, P = 0.036), nadir CD4+ (Spearman r = -0.800, P = 0.010), baseline CD4+ (Spearman r = -0.667, P = 0.049) and years with undetectable viral load (Spearman r = -0.717, P = 0.030). CONCLUSIONS: Despite a long period of HIV viral load suppression and a low viral reservoir, early and consistent viral rebound was observed during ATI in all subjects.
Authors: Thembi Mdluli; Yifan Li; Suteeraporn Pinyakorn; Daniel B Reeves; E Fabian Cardozo-Ojeda; Adam Yates; Jintana Intasan; Somporn Tipsuk; Nittaya Phanuphak; Carlo Sacdalan; Donn J Colby; Eugène Kroon; Trevor A Crowell; Rasmi Thomas; Merlin L Robb; Jintanat Ananworanich; Mark de Souza; Praphan Phanuphak; Daniel J Stieh; Frank L Tomaka; Lydie Trautmann; Julie A Ake; Denise C Hsu; Leilani V Francisco; Sandhya Vasan; Morgane Rolland Journal: Med (N Y) Date: 2022-07-22
Authors: Wesley de Jong; Lorna Leal; Jozefien Buyze; Pieter Pannus; Alberto Guardo; Maria Salgado; Beatriz Mothe; Jose Molto; Sara Moron-Lopez; Cristina Gálvez; Eric Florence; Guido Vanham; Eric van Gorp; Christian Brander; Sabine Allard; Kris Thielemans; Javier Martinez-Picado; Montserrat Plana; Felipe García; Rob A Gruters Journal: Vaccines (Basel) Date: 2019-12-06
Authors: Eva M Stevenson; Adam R Ward; Ronald Truong; Allison S Thomas; Szu-Han Huang; Thomas R Dilling; Sandra Terry; John K Bui; Talia M Mota; Ali Danesh; Guinevere Q Lee; Andrea Gramatica; Pragya Khadka; Winiffer D Conce Alberto; Rajesh T Gandhi; Deborah K McMahon; Christina M Lalama; Ronald J Bosch; Bernard Macatangay; Joshua C Cyktor; Joseph J Eron; John W Mellors; R Brad Jones Journal: JCI Insight Date: 2021-02-08
Authors: S Fidler; S Lewin; S Deeks; O S Sogaard; L Vanderkerckhove; S Collins; D Kelly; J Singh; M Caskey; J Frater Journal: J Virus Erad Date: 2020-12-06
Authors: Daniel Schmidt; Christian Kollan; Matthias Stoll; Osamah Hamouda; Viviane Bremer; Tobias Kurth; Barbara Bartmeyer Journal: BMC Public Health Date: 2021-01-22 Impact factor: 3.295
Authors: Camilla Muccini; Monica Guffanti; Vincenzo Spagnuolo; Massimo Cernuschi; Laura Galli; Alba Bigoloni; Andrea Galli; Andrea Poli; Sara Racca; Antonella Castagna Journal: PLoS One Date: 2022-03-15 Impact factor: 3.240